Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stevia extract takes step toward EU acceptance

This article was originally published in The Tan Sheet

Executive Summary

Steviol glycosides are neither genotoxic nor carcinogenic at an acceptable daily intake of 4 mg per kg of body weight daily, according to the European Food Safety Authority's scientific panel on additives. EFSA will submit its evaluation to the European Commission for consideration of whether the stevia extracts are safe to add to foods and beverages, the authority said April 14. In a same-day release, Truvia maker Cargill called the EFSA decision "a very important milestone in the path of European regulatory approval of steviol glycosides." EFSA's ADI determination for steviol glycosides is in line with that reached by the Joint Expert Committee on Food Additives of the World Health Organization and United Nations in 2008 (1"The Tan Sheet" Nov. 3, 2008)

You may also be interested in...

Stevia Nearing Sweet Taste Of Success, But Citizen Petition Could Spoil Party

Natural sweeteners derived from the stevia leaf appear mere months away from an international boom as a growing number of scientific and regulatory bodies approve the use of steviol glycosides in food and as major food and beverage players angle for a piece of the action

Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research

The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.

QUOTED. 10 December 2019. Viral Shah.

The global insulin pump market is expected to see significant growth, reaching $5.1bn by 2023. A new Market Intel story looks at the competitive landscape of the three leading companies in this market, Medtronic, Insulet and Tandem Diabetes Care, which are all expected to launch new products in 2020. See what Viral Shah, an assistant professor of medicine and pediatrics at the University of Colorado, said about the diabetes market here.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts